Chronic Selective Endothelin A Receptor Antagonism Reduces Serum Uric Acid in Hypertensive Chronic Kidney Disease-Reference-Cited by-同舟云学术

Chronic Selective Endothelin A Receptor Antagonism Reduces Serum Uric Acid in Hypertensive Chronic Kidney Disease

Published:2011-08 Issue:2 Volume:58 Page:
ISSN:0194-911X
Container-title:Hypertension
language:en
Short-container-title:Hypertension

Author:

Dhaun Neeraj¹,Johnston Neil R.²,Goddard Jane³,Webb David J.⁴

Affiliation:

1. Clinical Pharmacology Unit British Heart Foundation Centre of Research Excellence University of Edinburgh The Queen's Medical Research Institute Edinburgh, United Kingdom Department of Renal Medicine Royal Infirmary of Edinburgh Edinburgh, United Kingdom (Dhaun)

2. Clinical Pharmacology Unit British Heart Foundation Centre of Research Excellence University of Edinburgh The Queen's Medical Research Institute Edinburgh, United Kingdom (Johnston)

3. Department of Renal Medicine Royal Infirmary of Edinburgh Edinburgh, United Kingdom (Goddard)

4. Clinical Pharmacology Unit British Heart Foundation Centre of Research Excellence University of Edinburgh The Queen's Medical Research Institute Edinburgh, United Kingdom (Webb)

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Internal Medicine

Reference12 articles.

1. Uric Acid and Cardiovascular Risk

2. Serum Uric Acid and Cardiovascular Mortality

3. Uric Acid Level as a Risk Factor for Cardiovascular and All-Cause Mortality in Middle-aged Men

4. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort

5. Use of Allopurinol in Slowing the Progression of Renal Disease Through Its Ability to Lower Serum Uric Acid Level

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypertension: Current trends and future perspectives;British Journal of Clinical Pharmacology;2021-05-03

2. Endothelin receptor antagonists for pulmonary arterial hypertension;Cochrane Database of Systematic Reviews;2021-03-25

3. Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension;Hypertension;2020-04

4. A novel role for myeloid endothelin-B receptors in hypertension;European Heart Journal;2019-01-17

5. Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease;Nephrology Dialysis Transplantation;2014-11-21